OncoCyte (NYSEAMERICAN:OCX) is scheduled to be announcing its earnings results after the market closes on Thursday, November 14th. Analysts expect the company to announce earnings of ($0.09) per share for the quarter.
OncoCyte (NYSEAMERICAN:OCX) last posted its quarterly earnings results on Wednesday, August 14th. The biotechnology company reported ($0.10) EPS for the quarter, meeting the consensus estimate of ($0.10).
Shares of OncoCyte stock traded up $0.07 on Tuesday, reaching $1.71. The stock had a trading volume of 1,199 shares, compared to its average volume of 561,131. OncoCyte has a 1 year low of $1.16 and a 1 year high of $6.92.
In related news, CEO Thomas Alex Vetter bought 11,000 shares of the company’s stock in a transaction on Wednesday, September 11th. The shares were bought at an average price of $9.58 per share, with a total value of $105,380.00. Also, major shareholder Broadwood Partners, L.P. bought 2,000,000 shares of the company’s stock in a transaction on Wednesday, September 11th. The shares were bought at an average cost of $1.66 per share, for a total transaction of $3,320,000.00. In the last ninety days, insiders bought 2,071,000 shares of company stock worth $3,553,480.
OncoCyte Corporation focuses on the development and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer. The company is developing diagnostic tests using genetic and protein markers expressed in various types of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancer.
Featured Article: What type of investment options does a Roth IRA provide?
Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with MarketBeat.com's FREE daily email newsletter.